Cervical cancer screening: What’s new and what’s coming?

Jin, Xian Wen; Lipold, Laura; McKenzie, Margaret; Sikon, Andrea

doi:10.3949/ccjm.80a.12092

Cited by 19 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pap smear associated with DNA-HPV screening should be performed every five years after this age (in case they both present negative results) or Pap smear must be performed every three years in women older than 30 years. Screening can stop in women in the age group 65-years or older, when there is no history of high-grade intraepithelial lesions (LSIL) in the last twenty years [41] .…”

Section: Discussionmentioning

confidence: 99%

“…Besides, emphasis could be given to screening in women presenting higher risk to develop precursor lesions, such as the ones presenting high HPV risk. It is recommended to carry out the test in women older than 30 years, when there is chance of HPV persistence and, consequently, higher risk to develop lesions and cancer [41] . Some of the main measures to overcome health barriers and to fill the gaps between the target population in the planet would be to provide this test due to cost reduction and associate it with HPV vaccination programs subsidized by the government to the whole population [41] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Policies and Programs for Cervical Cancer Prevention and Control in Public Health Services

Sperling¹,

Coser

2018

Int J Innov Educ Res

View full text Add to dashboard Cite

Aim: analyzing and assessing the scientific evidences about Health Services Administration through the practice of cervical cancer prevention programs and policies. Methodology: integrative literature review carried out in September/October 2017. Electronic search for publications in databases such as PubMed, Portal Periódicos CAPES, BVS, EBSCO and SciELO. Results and Discussion: eighteen articles approaching the topic were selected and their analyses resulted in the following thematic axes: Organization of cervical cancer prevention and control policies/programs, Follow-up and monitoring of actions taken and Quality Management of Cytopathological exams for diagnostic and treatment. There were differences between programs in the country, either in their recommendations or in their effectiveness. Final considerations: investments must be done in order to qualify technical procedures and involved health professionals, as well as to support health education in the target population. Policies and Programs for

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Policies and Programs for Cervical Cancer Prevention and Control in Public Health Services

Sperling¹,

Coser

2018

Int J Innov Educ Res

View full text Add to dashboard Cite

show abstract

“…In 2009, US FDA approved genotyping test for HPV 16 and 18 (Cervista HPV 16/18). The risk of CIN III is 10% over 1-4 years and 2-5 years in women positive for HPV 16 and HPV 18 respectively (Jin et al, 2013;Villa and Denny, 2006).…”

Section: Human Papilloma Virus (Hpv)mentioning

confidence: 99%

“…The prevalence of HPV 16 and 18 reported is 10.7% in healthy cervix, 31.5% in cervicitis, 46.7% in CIN and 83.3% in squamous cell carcinoma. Hence the emergence of novel markers of HPV infection and cervical cancer screening that increase positive predictive value of current screening methods (Abreu et al, 2012;Apgar et al, 2009;Jin et al, 2013;Villa and Denny, 2006;Wright et al, 2007;Zhao et al, 2012).…”

Section: Human Papilloma Virus (Hpv)mentioning

confidence: 99%

See 1 more Smart Citation

Virus and Cervical Cancer: Role and implication: A Review

Raju

2014

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Cervical cancer is one of the leading cancers in women worldwide especially in developing countries. Various etiological factors are described, of which Human papillomavirus (HPV) is proved by various molecular epidemiological studies to play a major role. However, many co-factors are required and thought to facilitate the action of HPV in cervical carcinogenesis. Here the role of various viruses in cervical cancer and its implication in screening and diagnosis of cervical cancer is highlighted. In-depth knowledge of the role of different viruses helps in better screening methods and probably in target therapy / development of an appropriate vaccine.

show abstract

Cervical cancer screening by molecular Pap‐transformation of gynecologic cytology

Barodawala

Chadha

Kavishwar

et al. 2018

Diagnostic Cytopathology

View full text Add to dashboard Cite

Background Cervical cancer is one of the common cancers in women accounting for 7.9% of all cancers. In India it is the second commonest cancer in women. The immortality of the cancer cell and the relatively long time frame from acquisition of infection to development of cervical cancer was established. As major advancements like LBC, HPV testing were introduced in the recent years, screening has taken a new avatar, the Molecular pap!! The objectives of this study were: To compare gynecologic cytology and abnormal results with respect to conventional and LBC. To study the role of HPV cotesting and ancillary tests performed, that is, HPV CISH, and p16ink4a by IHC. Methods About 71 924 Conventional and LBC samples were included from August 2009 to December 2017. Cases for HPV testing along the conventional smears were 1539. HPV can be tested from the same LBC vial as the sample remains stable at room temperature for 6 weeks. HPV DNA PCR was carried out in our laboratory for High and Low risk genotypes. Cytology findings were also correlated with histology. Results Detection rate of SILs in LBC samples were higher (2.20%). The commonest abnormality was LSIL in LBC and ASCUS in conventional smears. Commonest HR HPV and LR HPV detected was 1 61 856 and 61 142. Conclusion LBC with HPV cotesting improves sensitivity and specificity and reduces ambiguous results; allows better compliance, as a negative result of both tests allows patients to get screening every 5 years, thereby increasing screening intervals, important in a resource limited situation.

show abstract

Cervical cancer screening: What’s new and what’s coming?

Abstract: In their 2012 guidelines for cervical cancer screening, several organizations call for less-frequent but more-effective screening that incorporates testing for human papillomavirus (HPV). We review these recommendations and the possible future direction of screening.

Cited by 19 publications

References 0 publications

Policies and Programs for Cervical Cancer Prevention and Control in Public Health Services

Policies and Programs for Cervical Cancer Prevention and Control in Public Health Services

Virus and Cervical Cancer: Role and implication: A Review

Cervical cancer screening by molecular Pap‐transformation of gynecologic cytology

Contact Info

Product

Resources

About